% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Rehbach:140787,
author = {Rehbach, Kristina and Kesavan, Jaideep and Hauser, Stefan
and Ritzenhofen, Swetlana and Jungverdorben, Johannes and
Schüle, Rebecca and Schöls, Ludger and Peitz, Michael and
Brüstle, Oliver},
title = {{M}ultiparametric rapid screening of neuronal process
pathology for drug target identification in {HSP}
patient-specific neurons.},
journal = {Scientific reports},
volume = {9},
number = {1},
issn = {2045-2322},
address = {[London]},
publisher = {Macmillan Publishers Limited, part of Springer Nature},
reportid = {DZNE-2020-07109},
pages = {9615},
year = {2019},
abstract = {Axonal degeneration is a key pathology of neurodegenerative
diseases, including hereditary spastic paraplegia (HSP), a
disorder characterized by spasticity in the lower limbs.
Treatments for HSP and other neurodegenerative diseases are
mainly symptomatic. While iPSC-derived neurons are valuable
for drug discovery and target identification, these
applications require robust differentiation paradigms and
rapid phenotypic read-outs ranging between hours and a few
days. Using spastic paraplegia type 4 (SPG4, the most
frequent HSP subtype) as an exemplar, we here present three
rapid phenotypic assays for uncovering neuronal process
pathologies in iPSC-derived glutamatergic cortical neurons.
Specifically, these assays detected a $51\%$ reduction in
neurite outgrowth and a $60\%$ increase in growth cone area
already 24 hours after plating; axonal swellings, a
hallmark of HSP pathology, was discernible after only 5
days. Remarkably, the identified phenotypes were neuron
subtype-specific and not detectable in SPG4-derived
GABAergic forebrain neurons. We transferred all three
phenotypic assays to a 96-well setup, applied small
molecules and found that a liver X receptor (LXR) agonist
rescued all three phenotypes in HSP neurons, providing a
potential drug target for HSP treatment. We expect this
multiparametric and rapid phenotyping approach to accelerate
development of therapeutic compounds for HSP and other
neurodegenerative diseases.},
keywords = {Biomarkers / Cell Differentiation / Cells, Cultured / Drug
Discovery: methods / Drug Evaluation, Preclinical: methods /
Haploinsufficiency / Humans / Induced Pluripotent Stem
Cells: cytology / Induced Pluripotent Stem Cells: drug
effects / Induced Pluripotent Stem Cells: metabolism /
Neural Stem Cells: cytology / Neural Stem Cells: drug
effects / Neural Stem Cells: metabolism / Neuronal Outgrowth
/ Neurons: drug effects / Neurons: metabolism / Phenotype /
Spastic Paraplegia, Hereditary: drug therapy / Spastic
Paraplegia, Hereditary: etiology / Spastic Paraplegia,
Hereditary: metabolism / Spastin: genetics},
cin = {AG Schöls / Cell Programming Unit / AG Maetzler},
ddc = {600},
cid = {I:(DE-2719)5000005 / I:(DE-2719)1013013 /
I:(DE-2719)5000024},
pnm = {345 - Population Studies and Genetics (POF3-345) / 344 -
Clinical and Health Care Research (POF3-344)},
pid = {G:(DE-HGF)POF3-345 / G:(DE-HGF)POF3-344},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:31270336},
pmc = {pmc:PMC6610147},
doi = {10.1038/s41598-019-45246-4},
url = {https://pub.dzne.de/record/140787},
}